Drug Approval | July 24, 2022
Dr. Reddy's announces the first-to-market, OTC launch of Allegra-D in the US market
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
Alopecia areata usually presents as a few small bald patches in the head
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
The Toradol tablets, 10 mg brand and generic had U.S. sales of approximately US $ 16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
